Third Rock-launched Pliant is latest biotech to climb on public debut
Three more biotechs hope to price deals on NASDAQ this week
Pliant joins a slew of recent biotechs that have seen substantial first-day gains.
The fibrosis company closed up $5.30 (33%) to $21.30 on Wednesday after raising $144 million through the sale of
